208 related articles for article (PubMed ID: 11850708)
1. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.
Park SH; Lee MH; Lee H; Kim HS; Kim K; Kim WS; Jung CW; Im YH; Yoon SS; Kang WK; Park K; Park CH; Kim SW
Bone Marrow Transplant; 2002 Jan; 29(2):137-43. PubMed ID: 11850708
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
[TBL] [Abstract][Full Text] [Related]
3. Low incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation attributed to a combination of intravenous heparin, oral glutamine, and ursodiol at a single transplant institution.
Lakshminarayanan S; Sahdev I; Goyal M; Vlachos A; Atlas M; Lipton JM
Pediatr Transplant; 2010 Aug; 14(5):618-21. PubMed ID: 20051023
[TBL] [Abstract][Full Text] [Related]
4. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients.
Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Callander NS; Clement DJ
Bone Marrow Transplant; 1992 Oct; 10(4):367-72. PubMed ID: 1422493
[TBL] [Abstract][Full Text] [Related]
5. Ursodiol to prevent hepatic venoocclusive disease.
Comcowich SA; Spitzer TR; Tsunoda SM
Ann Pharmacother; 1997 Oct; 31(10):1249-52. PubMed ID: 9337452
[TBL] [Abstract][Full Text] [Related]
6. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.
Simon M; Hahn T; Ford LA; Anderson B; Swinnich D; Baer MR; Bambach B; Bernstein SH; Bernstein ZP; Czuczman MS; Slack JL; Wetzler M; Herzig G; Schriber J; McCarthy PL
Bone Marrow Transplant; 2001 Mar; 27(6):627-33. PubMed ID: 11319593
[TBL] [Abstract][Full Text] [Related]
7. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
[TBL] [Abstract][Full Text] [Related]
8. [Efficiency of prevention and treatment of veno-occlusive disease of the liver after allogeneic stem cell transplantation].
Dong M; Lin Q; Wu XY
Ai Zheng; 2008 Jun; 27(6):646-9. PubMed ID: 18570742
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of hepatic veno-occlusive disease by a combination of heparin and prostaglandin E1 in children undergoing hematopoietic stem cell transplantation].
Inukai T; Sugita K; Goi K; Akahane K; Hirose K; Nemoto A; Takahashi K; Sato H; Uno K; Furuichi Y; Nakamura M; Miyamoto N; Yamakawa N; Shiraishi K; Kojika S; Tezuka T; Iijima K; Nakazawa S
Rinsho Ketsueki; 2004 Apr; 45(4):297-303. PubMed ID: 15168445
[TBL] [Abstract][Full Text] [Related]
10. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
[TBL] [Abstract][Full Text] [Related]
11. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection.
Moscardó F; Sanz GF; de La Rubia J; Jiménez C; Saavedra S; Regadera A; Andreu R; García I; Plumé G; Martínez J; Martín G; Jarque I; Sanz MA
Bone Marrow Transplant; 2001 May; 27(9):983-8. PubMed ID: 11436110
[TBL] [Abstract][Full Text] [Related]
12. How can we reduce hepatic veno-occlusive disease-related deaths after allogeneic stem cell transplantation?
Johnson DB; Savani BN
Exp Hematol; 2012 Jul; 40(7):513-7. PubMed ID: 22542577
[TBL] [Abstract][Full Text] [Related]
13. Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center study.
Tanikawa S; Mori S; Ohhashi K; Akiyama H; Sasaki T; Kaku H; Hiruma K; Matsunaga T; Morita T; Sakamaki H
Bone Marrow Transplant; 2000 Oct; 26(8):881-6. PubMed ID: 11081389
[TBL] [Abstract][Full Text] [Related]
14. Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation.
Batsis I; Yannaki E; Kaloyannidis P; Sakellari I; Smias C; Georgoulis I; Fassas A; Anagnostopoulos A
Thromb Res; 2006; 118(5):611-8. PubMed ID: 16330084
[TBL] [Abstract][Full Text] [Related]
15. [Low dose heparin for the prevention of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation].
Chen J; Zhu KE; Zhang T; Zhong J; Chen ST; Zeng HL
Zhonghua Nei Ke Za Zhi; 2007 Feb; 46(2):140-2. PubMed ID: 17445443
[TBL] [Abstract][Full Text] [Related]
16. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone.
Al Beihany A; Al Omar H; Sahovic E; Chaudhri N; Al Mohareb F; Al Sharif F; Al Zahrani H; Al Shanqeeti A; Seth P; Zaidi S; Morshed M; Al Anazi K; Mohamed G; Gyger M; Aljurf M
Bone Marrow Transplant; 2008 Feb; 41(3):287-91. PubMed ID: 17982501
[TBL] [Abstract][Full Text] [Related]
18. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation.
Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Andreesen R; Kolb HJ; Holler E; Pihusch R
Bone Marrow Transplant; 2005 Oct; 36(7):631-7. PubMed ID: 16062176
[TBL] [Abstract][Full Text] [Related]
19. Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
Lee SH; Yoo KH; Sung KW; Koo HH; Kwon YJ; Kwon MM; Park HJ; Park BK; Kim YY; Park JA; Im HJ; Seo JJ; Kang HJ; Shin HY; Ahn HS
Bone Marrow Transplant; 2010 Aug; 45(8):1287-93. PubMed ID: 20010866
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic low-dose heparin or prostaglandin E1 may prevent severe veno-occlusive disease of the liver after allogeneic hematopoietic stem cell transplantation in Korean children.
Song JS; Seo JJ; Moon HN; Ghim T; Im HJ
J Korean Med Sci; 2006 Oct; 21(5):897-903. PubMed ID: 17043426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
